EMA to hold public hearing on safety of valproate medicines

This is the first time the EMA’s Pharmacovigilance Risk Assessment Committee has held a public hearing during a safety review.
This is the first time the EMA’s Pharmacovigilance Risk Assessment Committee has held a public hearing during a safety review.